Iovance Biotherapeutics Stock Rises Premarket on Positive Trial Data for Cancer Drug

Dow Jones

Nov 03, 2025

By Adriano Marchese

Iovance Biotherapeutics shares rose after the company received positive data from a clinical trial of its cancer treatment.

Shares traded 11% higher ahead of the morning bell at $2.18.

The biotechnology company, which specializes in cell therapies for cancer, on Monday said that about 26% of patients responded to the lifileucel monotherapy treatment in Phase 2 testing, including two who saw their cancer disappear. The San Carlos, Calif., company said the disease-control rate, or the proportion of patients who had their disease stabilize or improve, was at about 72%.

Iovance said it plans to present more data in 2026 and hopes to progress toward a biologics license application with the Food and Drug Administration next year as well. It aims for a potential launch in the second half of 2027, it said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

November 03, 2025 09:25 ET (14:25 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580921193"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580921193\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580921193?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 22:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580921193","market":"other","top_or_hot":-1,"title":"Iovance Biotherapeutics Stock Rises Premarket on Positive Trial Data for Cancer Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics</a> shares rose after the company received positive data from a clinical trial of its cancer treatment. \n</p>\n<p>\n  Shares traded 11% higher ahead of the morning bell at $2.18. \n</p>\n<p>\n  The biotechnology company, which specializes in cell therapies for cancer, on Monday said that about 26% of patients responded to the lifileucel monotherapy treatment in Phase 2 testing, including two who saw their cancer disappear. The San Carlos, Calif., company said the disease-control rate, or the proportion of patients who had their disease stabilize or improve, was at about 72%. \n</p>\n<p>\n  Iovance said it plans to present more data in 2026 and hopes to progress toward a biologics license application with the Food and Drug Administration next year as well. It aims for a potential launch in the second half of 2027, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 09:25 ET (14:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance Biotherapeutics Stock Rises Premarket on Positive Trial Data for Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance Biotherapeutics Stock Rises Premarket on Positive Trial Data for Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-03 22:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics</a> shares rose after the company received positive data from a clinical trial of its cancer treatment. \n</p>\n<p>\n  Shares traded 11% higher ahead of the morning bell at $2.18. \n</p>\n<p>\n  The biotechnology company, which specializes in cell therapies for cancer, on Monday said that about 26% of patients responded to the lifileucel monotherapy treatment in Phase 2 testing, including two who saw their cancer disappear. The San Carlos, Calif., company said the disease-control rate, or the proportion of patients who had their disease stabilize or improve, was at about 72%. \n</p>\n<p>\n  Iovance said it plans to present more data in 2026 and hopes to progress toward a biologics license application with the Food and Drug Administration next year as well. It aims for a potential launch in the second half of 2027, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 09:25 ET (14:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2580921193","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580921193","pubTimestamp":1762179900,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Iovance Biotherapeutics shares rose after the company received positive data from a clinical trial of its cancer treatment.Shares traded 11% higher ahead of the morning bell at $2.18.The biotechnology company, which specializes in cell therapies for cancer, on Monday said that about 26% of patients responded to the lifileucel monotherapy treatment in Phase 2 testing, including two who saw their cancer disappear. The San Carlos, Calif., company said the disease-control rate, or the proportion of patients who had their disease stabilize or improve, was at about 72%.Iovance said it plans to present more data in 2026 and hopes to progress toward a biologics license application with the Food and Drug Administration next year as well. It aims for a potential launch in the second half of 2027, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"Iovance Biotherapeutics股价因癌症药物试验数据积极而盘前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\nIovance Biotherapeutics shares rose after the company received positive data from a clinical trial of its cancer treatment. \n\n\n  Shares traded 11% higher ahead of the morning bell at $2.18. \n\n\n  The biotechnology company, which specializes in cell therapies for cancer, on Monday said that about 26% of patients responded to the lifileucel monotherapy treatment in Phase 2 testing, including two who saw their cancer disappear. The San Carlos, Calif., company said the disease-control rate, or the proportion of patients who had their disease stabilize or improve, was at about 72%. \n\n\n  Iovance said it plans to present more data in 2026 and hopes to progress toward a biologics license application with the Food and Drug Administration next year as well. It aims for a potential launch in the second half of 2027, it said. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 09:25 ET (14:25 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}